• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
All
Options & Futures
Funds
IPO Subscription
Structured Products
Investment Wiki
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List

KalVista Pharma(KALV.US)

Overview
News
Financials
© 2026 Longbridge|Disclaimer

Event Tracking

Nov4
KalVista Pharma to release FY2025 Q3 earnings on November 11 Pre-Market EST, forecast revenue USD 4.2 M, EPS USD -1.02
00:08
Sep29
KalVista Pharmaceuticals Proposes $110 Million Convertible Senior Notes Offering
20:28
Sep26
KalVista to Present New Data on EKTERLY for HAE at German Allergy Congress
11:00
Sep24
KalVista Pharmaceuticals Announces $110 Million Convertible Debt Offering, Shares Drop 10.3%
20:26
Sep19
KalVista Pharmaceuticals Obtains EU and Swiss Approval for EKTERLY® and Plans for Market Launch
11:00
Sep11
KalVista Pharma released FY2026 Q1 earnings on September 11 Pre-Market EST, actual revenue USD 1.426 M (forecast USD 2.089 M), actual EPS USD -1.1233 (forecast USD -0.955)
13:30

Schedules & Filings

Schedules
Filings
Sep11
Earning Release(EST)

FY2026 Q1 Earning Release (USD) Revenue 1.426 M, Net Income -60.1 M, EPS -1.1233

Jul10
Earning Release(EST)

FY2025 Q4 Earning Release (USD) Net Income -52.23 M, EPS -0.9845

Mar12
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -48.51 M, EPS -0.9215

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
INBS
9.530
+132.44%
+5.430
ANGH
3.770
+62.50%
+1.450
WTO
1.020
+61.09%
+0.387
ESHAR
0.2500
+47.06%
+0.080
NCL
0.2731
+40.77%
+0.079
FGMCR
0.5500
+33.50%
+0.138
ESHA
19.180
+33.38%
+4.800
IPEXR
0.8000
+31.97%
+0.194
RDACR
0.2400
+26.32%
+0.050
DVLT
0.6521
+26.25%
+0.136
View More